Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 13639

1.

Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.

Nowroozi M, Ayati M, Jamshidian H, Arbab A, Ghorbani H, Amini E, Hakima H, Salehi S, Ghadian A.

Nephrourol Mon. 2015 Mar 20;7(2):e26752. doi: 10.5812/numonthly.26752. eCollection 2015 Mar.

2.

[Prostate cancer of unknown primary origin with multiple lymph nodes metastasis; a case report].

Haraoka M, Takamuki M, Toyonaga Y, Tanaka M, Hanazawa K, Sakamoto Y, Horie S.

Nihon Hinyokika Gakkai Zasshi. 2014 Oct;105(4):212-7. Japanese.

PMID:
25757353
3.

Comparison of pathological and biochemical outcomes after radical prostatectomy in Korean patients with serum PSA ranges.

Lee HW, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

J Korean Med Sci. 2015 Mar;30(3):317-22. doi: 10.3346/jkms.2015.30.3.317. Epub 2015 Feb 16.

4.

[Evaluation of prostate cancer progression].

Mocarska A, Czarnocki K, Starosławska E, Janczarek M, Zelazowska-Cieslińska I, Losicki M, Burdan F.

Pol Merkur Lekarski. 2014 Dec;37(222):356-64. Review. Polish.

PMID:
25715578
5.

Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.

Afshar M, Al-Alloosh F, Pirrie S, Rowan C, James ND, Porfiri E.

Anticancer Res. 2015 Feb;35(2):1057-63.

PMID:
25667494
6.

Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results.

Abdi H, Zargar H, Goldenberg SL, Walshe T, Pourmalek F, Eddy C, Chang SD, Gleave ME, Harris AC, So AI, Machan L, Black PC.

Urol Oncol. 2015 Feb 6. pii: S1078-1439(15)00006-X. doi: 10.1016/j.urolonc.2015.01.004. [Epub ahead of print]

PMID:
25665509
7.

Mixed epithelial-stromal tumor (MEST) of seminal vesicle: a proposal for unified nomenclature.

Reikie BA, Yilmaz A, Medlicott S, Trpkov K.

Adv Anat Pathol. 2015 Mar;22(2):113-20. doi: 10.1097/PAP.0000000000000057.

PMID:
25664946
8.

[Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].

Grenader T, Plotkin Y, Rosengarten O.

Harefuah. 2014 Dec;153(12):731-4, 752. Hebrew.

PMID:
25654915
9.

Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men.

de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, Siddiqui J, Mosquera JM, Rubin MA, Sanda MG.

J Urol. 2015 Jan 28. pii: S0022-5347(15)00183-4. doi: 10.1016/j.juro.2015.01.091. [Epub ahead of print]

PMID:
25636659
10.

Researchers look to MRI and biomarkers to help improve detection of aggressive prostate cancers.

Rubin R.

JAMA. 2015 Feb 17;313(7):654-6. doi: 10.1001/jama.2015.169. No abstract available.

PMID:
25629168
11.

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA.

JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.

PMID:
25626035
12.

Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States.

Weiner AB, Patel SG, Eggener SE.

Urol Oncol. 2015 Jan 23. pii: S1078-1439(14)00465-7. doi: 10.1016/j.urolonc.2014.12.012. [Epub ahead of print]

PMID:
25624093
13.

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK.

J Urol. 2015 Jan 24. pii: S0022-5347(15)00168-8. doi: 10.1016/j.juro.2015.01.078. [Epub ahead of print]

PMID:
25623747
14.

The primary local stage at diagnosis predicts regional symptoms caused by local progression in patients with castration-resistant prostate cancer.

Hashimoto K, Mizuno T, Kitamura H, Shindo T, Takahashi S, Masumori N.

Urology. 2015 Feb;85(2):430-5. doi: 10.1016/j.urology.2014.09.044.

PMID:
25623712
15.

Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients.

Riedel DJ, Cox ER, Stafford KA, Gilliam BL.

Urology. 2015 Feb;85(2):415-21. doi: 10.1016/j.urology.2014.09.054. Epub 2014 Nov 4.

PMID:
25623706
16.

Decision analysis of dutasteride use for patients with negative prostate biopsy.

Vickers AJ, Sjoberg DD.

Urology. 2015 Feb;85(2):337-41. doi: 10.1016/j.urology.2014.08.048.

PMID:
25623680
17.

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R.

J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63. Review.

PMID:
25620167
18.

Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.

Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL.

Eur Urol. 2015 Jan 21. pii: S0302-2838(15)00018-4. doi: 10.1016/j.eururo.2015.01.004. [Epub ahead of print] Review.

PMID:
25616709
19.

[Modern therapy of prostate cancer].

Kretschmer A, Stief C, Gratzke C.

MMW Fortschr Med. 2014 Dec 15;156(21-22):71-3. Review. German. No abstract available.

PMID:
25608415
20.

How active should active surveillance be?

Eggener S.

BJU Int. 2015 Feb;115(2):176-7. doi: 10.1111/bju.12859. No abstract available.

PMID:
25604714
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk